UNSPSC 51332837: Carfenazine maleate

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C24H31N3O2S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0HX1Z0A2MC, chemically known as 1-propanone, 1-(10-(3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-, maleate (1:2) (salt) but more generally known as carfenazine maleate, which bears US NIH Compound Identifier 6433356. Carfenazine most often comes in base and maleate forms.

European Medicines Agency schedules Carfenazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01059MIG. Most nations, for tariff and trade purposes, schedule carfenazine maleate under HS 29343090. SMILES: CCC(=O)C1CC2C(CC1)SC3C(CCCC3)N2CCCN4CCN(CC4)CCO.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332837 Carfenazine maleate (Commodity) shows limited recent state and local procurement activity directly aligned with the code. The three recent opportunities tagged to this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products — none of which explicitly name carfenazine maleate as a procurement target. The code appears to describe a specific pharmaceutical ingredient or formulation with narrow application in state and local government procurement, yet the available records do not reflect active solicitation for this product itself.

The issuing bodies in the recent records span state health agencies and cooperative purchasing alliances: Seminole County, Florida (community health procurement); Texas Health and Human Services Commission (pharmaceutical benefit program strategy); and Minnesota Multistate Cooperative Purchasing Alliance (multi-state generic pharmaceutical contracting). The geographic spread reflects Florida, Texas, and Minnesota participation, with the MMCAP cooperative extending to Oregon. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Texas HHS RFI (HHS0017013, closed April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription programs. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products across state and local facilities. None of these records specifically name carfenazine maleate procurement, indicating the code may have limited current relevance to active state and local opportunities.